Aim: To investigate the roles of P21-activated kinase 5 (PAK5) in proliferation and tumorigenicity of human hepatocellular carcinoma (HCC). Methods: HCC and matched paraneoplastictis tissue samples were obtained from 30 patients. Human HCC cell lines SMMC7721, HepG2, Hep3B, SK-HEP-1, Huh-7, and liver cell line HL-7702 were examined. The expression of PAK5 gene was studied using real-time qPCR and Western blotting. Cell proliferation was quantified with the MTT assay. Cell cycle was analyzed with flow cytometry. The tumorigenicity of Lv-shRNA-transfected HepG2 cells was evaluated in BALB/cA nude mice. Results: The mRNA level of PAK5 was significantly higher in 25 out of 30 HCC samples compared to the matched paraneoplastic tissues. The HCC cell lines showed varying expression of PAK5 protein, and the highest level was found in the HepG2 cells. PAK5 gene silencing in HepG2 cells markedly reduced the cell proliferation and colony formation, and induced cell cycle arrest in the G 1 phase. Furthermore, PAK5 gene silencing suppressed the tumor formation in nude mice, and significantly decreased the expression of HCCrelated genes Cyclin D1 and beta-catenin. Conclusion: PAK5 may play essential roles in the initiation and progression of human HCC. Thus, it may be an effective therapeutic target or perhaps serve as a clinical diagnostic or prognostic marker in human HCC.
Introduction
P21-activated kinases (PAKs) are a family of serine/threonine kinases that play an important role in regulating cell shape, movement, proliferation and survival [1, 2] . PAKs are characterized by a highly conserved amino-terminal Cdc42/Rac interactive binding (CRIB) domain and a carboxyl terminal kinase domain [3] . PAKs are categorized into group I (PAK1, 2, and 3) and II (PAK4, 5, and 6) based on their amino acid sequences and functions [4] . PAK5 is the latest PAK family member to be identified, in 2002, and is considered a group II PAK based on its sequence [5] . Previous work by several groups has found that PAK5 has different properties from those of other members of the PAK family; for example, the Cdc42/Rac GTPase binds to PAK5 but does not regulate PAK5 kinase activity [6] . Unlike the group I PAKs, binding of Cdc42 is not necessary for the kinase activity of PAK5 [5] . Additionally, the CRIB domain of PAK5 is critical for appropriate subcellular localization of the protein [7] , and this localization is independent of kinase activity or Cdc42 binding [6] . PAK5 phosphorylates BAD on Ser-112, which prevents the localization of BAD to the mitochondria and inhibits the apoptotic cascade [6] . Finally, the multiple locations of the protein indicate that PAK5 most likely plays an important role in distinct signaling pathways. Research suggests that both, the mitochondrial localization and kinase activity of PAK5, are vital to its effects on apoptosis [6, 8] . PAK5 is primarily expressed in adult neuronal tissue [9] , with higher levels of expression detected in the cerebellum, cerebral cortex and olfactory bulb [5] . PAK5 has been found to regulate neurite development by operating downstream of Cdc42 and # These authors contributed equally to this work. * To whom correspondence should be addressed.
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Acta Pharmacologica Sinica npg Rac and antagonizing Rho in this pathway [9] . The other members of the PAK family have been identified as regulators of tumor formation in the breast [10] , colon [11] , ovary [12] , pancreas [13] , and prostate [14] . Although the role of PAK5 in cancer progression has not been fully investigated, two recent reports suggest that PAK5 is overexpressed in colorectal cancer and can promote cancer-cell invasion [15, 16] . Furthermore, the combined inhibition of PAK7, MAP3K7, and CK2a kinases was shown to inhibit the growth of MiaPaCa2 pancreatic cancer cell xenografts [17] . Hepatocellular carcinoma (HCC) is the most common human cancer, with approximately 750 000 new cases occurring worldwide each year [18] . Despite its high prevalence, the molecular mechanisms underlying HCC initiation, maintenance, and progression are poorly understood. As noted above, the significance of PAK5 in cancer cell biology is being studied although its function in HCC remains unknown. In our current study, we found that PAK5 gene expression is highly elevated in HCC cell lines and tumor samples. Moreover, silencing PAK5 gene expression in the HCC cell line HepG2 significantly reduced cell proliferation and colony formation in vitro, tumor formation in nude mice, and HCCrelated gene expression. Thus, these studies provide new insight into the biological effects of PAK5 in HCC and may be a useful reference for clinical diagnosis of HCC.
Materials and methods

Tissue preparation
The tissue samples utilized in this study were collected retrospectively from 30 HCC patients; the disease was confirmed by histopathological analyses after surgical resection. Paraneoplastic tissues were also obtained from the same group of 30 patients. All paraffin-embedded human tissue samples were archival remnants of tissues resected for clinical purposes and were obtained from the Department of Hepatobiliary Surgery of Taizhou Hospital (Linhai, China). Tissue samples were collected and used for qPCR and immunohistochemical assays to measure PAK5 gene expression. The study was performed in accordance with the ethical standards of the Helsinki Declaration.
Cell culture
The HCC cell lines SMMC7721, HepG2, Hep3B, SK-HEP-1, and Huh-7 and the liver cell line HL-7702 (L-02) were purchased from the American Type Culture Collection. These cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovin serum (FBS, Invitrogen, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA, USA). All cells were maintained in 5% CO 2 .
Lentiviral vector construction, lentivirus packaging, and trans fection Oligodeoxyribonucleotides encoding two different short hairpin RNAs (shRNA) targeting PAK5 (GenBank Accession: NM 020341.3) were designed and cloned into the pGCSIL-GFP plasmid vector (GeneChem, Shanghai, China). This plasmid contains a CMV-driven eGFP reporter and a U6 promoter upstream of the restriction enzyme sites for Age I and EcoR I used for cloning. Restriction enzyme mapping and DNA sequencing helped confirm the appropriate insertion of the shRNA cassettes. The scrambled sequence 5'-TTCTCCGAA-CGTGTCACGT-3' was cloned and used as a negative control (scr-shRNA). The top-strand sequences of the deoxyribonucleotides used for cloning were as follows: PAK5-shRNA1, 5'-CCGGGCCTCCATAAATATGATCTATCTCGAGATA-GATCATATTTATGGAGGCTTTTT-3'; and PAK5-shRNA2, 5'-CCGGCGGGATTACCACCATGACAATCTCGAGATTGTCA-TGGTGGTAATCCCGTTTTT-3'. Lentiviruses were packaged and purified to yield Lv-PAK5-shRNA1, Lv-PAK5-shRNA2, and Lv-scr-shRNA, which were used to transfect cells using previously reported methods [19] . Silencing by PAK5-targeted shRNAs was confirmed by qPCR and Western blotting assays.
RNA extraction and realtime quantitative PCR (qPCR)
RNA was extracted from cell lines, hepatocellular carcinomas and paraneoplastic tissues with TRIzol Reagent (Gibco BRL) according to the manufacturer's instructions. Two micrograms of RNA per sample was reverse transcribed into cDNA with reverse transcriptase (MMLV-RT, Promega) using a standard protocol with random hexamer primers. MMLV was omitted in the negative control. The qPCR reactions were performed by the two-step method according to the manufacturer's instructions. Amplification was performed under the following conditions: an initial denaturation cycle at 95 °C for 15 s, 45 cycles of denaturation at 95 °C for 15 s and annealing at 60 °C for 15 s. The resulting data were analyzed with the Gene Amp Sequence Detection System (Applied Biosystems, Foster City, CA, USA), and the Ct values of the samples were normalized using GAPDH as the internal control. The expression levels of PAK5 were plotted as the log2 of the ratio between the tumor and the paraneoplastic tissue samples.
Immunohistochemical analysis
Immunohistochemistry was performed using the avidin-biotin complex protocol for paraffin-embedded tissues as previously described [20] . Antigen retrieval was performed in 10 mmol/L citrate buffer, pH 6, using a pressure cooker. The antibodies used, namely anti-PAK5 antibody (ab110069, 1:100) and goat anti-rabbit IgG-H&L (HRP) (ab6721, 1:100), were acquired from Abcam (Cambridge, MA, USA). For the negative controls, the primary antibody was substituted with rabbit IgG.
Western blotting
The cells were washed twice with PBS, resuspended in 2×Lysis Buffer [100 mmol/L Tris-HCl (pH 6.8), 2% mercaptoethanol, 20% glycerol and 4% SDS], and incubated on ice for 10-15 min. The cells were lysed by ultrasonication and centrifuged at 12 000×g for 15 min at 4 °C. The protein concentrations of the supernatants were measured by the Bradford assay and adjusted to 2 μg/μL protein. An equal volume of 2×loading buffer was added, and the samples were boiled for 5-10 min Cell proliferation assay Cellular proliferation was quantified over a course of five days post-transfection by the MTT assay (Trevigen, Gaithersburg, MD, USA) according to the manufacturer's instructions. Briefly, cells were seeded in 96-well culture plates with culture medium at a density of 5×10 3 cells per well in triplicate wells for the Lv-PAK5-shRNA1, Lv-PAK5-shRNA2, and Lv-scrshRNA groups. Absorbance was measured at 490 nm with a microtiter plate reader. The values were averaged from triplicate wells at each time point.
Cell cycle assay
The cells were harvested, washed twice with D-Hanks' medium, and fixed in 70% ethanol at 4 ºC overnight. Subsequently, the cells were collected by centrifugation and stained with propidium iodide (PI) (50 µg/mL). RNase A (20 µg/mL) was then added, and the samples were incubated for 30 min at 37 °C. Cell cycle analysis was performed with the BD FACS Calibur (Becton Dickinson, San Jose, CA, USA), and the cell cycle phases were analyzed with FlowJo and FCS3.0 software.
Colony formation assay
To determine substrate-independent cell growth, soft agar assays were performed in 6-well plates with a 1.5-mL bottom layer and a 0.5-mL top layer. Cells (1×10 4 /well) were distributed as a cell suspension in 3.4 mg/mL agar (Difco Laboratories, Detroit, MI, USA) in the assay medium and overlaid onto a bottom layer consisting of 5.1 mg/mL agar in the assay medium. The cells were incubated for 2 to 3 h at room temperature and then transferred to 37 °C, 5% CO 2 . The cell layer was covered with 400 µL of fresh assay medium every two days, and the colonies were Giemsa stained and counted after 10 d.
Tumorigenicity assay with nude mice
The tumorigenicity of Lv-shRNA transfected HepG2 cells was evaluated in BALB/cA nude mice (Taconic). The concentration of the cell suspensions was adjusted to 5×10 7 /mL. Mice were subcutaneously injected with 0.2 mL of the cell suspension from Lv-PAK5-shRNA1, Lv-PAK5-shRNA2, or Lv-scrshRNA transfected cells (n=5 mice per group), in the right lateral aspect of the thoracic wall. The mice were inspected for tumor growth three times a week. Animal care practices and all experiments were reviewed and approved by the Animal Committee of Tongji University School of Medicine, Shanghai, China (TJmed-010-10).
Statistical analysis
The data were analyzed by one-way ANOVA with SPSS 12.0. P<0.05 was considered statistically significant. Error bars represent the standard deviations.
Results
Elevated expression of PAK5 in HCC tissues and HCC cell lines PAK5 gene expression in HCC tissues was compared to that in matched paraneoplastic tissues by qPCR and immunohistochemical analysis. PAK5 mRNA was significantly higher in 25 of 30 HCC samples (83.33%, P<0.05) than that in the corresponding paraneoplastic tissues ( Figure 1B) . Likewise, immunohistochemical analysis showed higher levels of PAK5 protein in the tumor samples ( Figure 1A ). The expression of PAK5 protein was also examined in a number of human tumor cell lines, including HCC (SMMC7721, HepG2, Hep3B, SK-HEP-1, and Huh-7), and liver cells (HL-7702). The tumor cell lines presented varying levels of PAK5 protein, and the highest expression in the tumor cell lines was observed in the HepG2 cells (P<0.05) ( Figure 1C ). Based on these results, we decided to examine the effects of PAK5 on cellular proliferation and tumorigenicity, employing HepG2 cells as a model.
Effects of PAK5 gene silencing on cell function
To examine the biological effects of PAK5, we designed two shRNA expression constructs for lentivirus-mediated gene silencing and used scr-shRNA as the control. The constructs also expressed GFP to assess transfection efficiency by fluorescence microscopy. At an MOI of 40, all three lentiviruses transfected HepG2 cells at a high efficiency as observed at 72 h (Figure 2A ). Compared to Lv-scr-shRNA transfected cells, both Lv-PAK5-shRNA1 and Lv-PAK5-shRNA2 reduced the PAK5 mRNA levels by ~75% ( Figure 2B ; P<0.05), and at the protein level, Lv-PAK5-shRNA2 appeared slightly more effective than Lv-PAK5-shRNA1 ( Figure 2C ). These results demonstrate the efficacy of the lentivirus constructs for PAK5 silencing.
The biological effects of PAK5 silencing in HepG2 cells were further assessed by examining cell proliferation, colony formation in soft agar, and cell cycle distribution. Three days following the transfection of HepG2 cells with Lv-scr-shRNA, Lv-PAK5-shRNA1, or Lv-PAK5-shRNA2, cell proliferation was measured by the MTT assay over the ensuing five days. Transfection with either Lv-PAK5-shRNA construct markedly reduced cell proliferation compared with Lv-scr-shRNA transfected cells ( Figure 3A, P<0.05) . Likewise, PAK5 gene silencing strongly inhibited the ability of HepG2 cells to form colonies in soft agar ( Figure 3B ). Finally, flow cytometry was used to measure the DNA content of transfected cells, and the distribution of cells in the G 1 , S, and G 2 /M phases was measured. The fraction of Lv-PAK5-shRNA1-and Lv-PAK5-shRNA2-transfected cells in the G 1 phase increased to 64% and 58%, respectively, with PAK5 gene silencing compared with 37% of Lv-scr-shRNA-transfected control cells in the G 1 phase ( Figure 3C, lower panel, P<0.05 ). In addition, the fraction of cells in the S phase decreased upon PAK5 gene silencing. All PAK5 gene silencing suppresses hepatocellular cancerrelated gene expression Genes encoding Cyclin D1 and beta-catenin have been implicated in hepatocellular carcinoma [21] [22] [23] [24] [25] [26] . To determine whether PAK5 gene silencing affects the expression of these genes, HepG2 cells were transfected with the Lv-PAK5-shRNAs or control Lv-scr-shRNA as before, and the expression of Cyclin D1 and beta-catenin were analyzed by qPCR and Western blotting. We found that silencing of PAK5 reduced the mRNA expression of both Cyclin D1 and beta-catenin by 70%-80% compared to the control shRNA ( Figure 4A, P<0.05) . Similarly, knockdown of PAK5 protein reduced the expression of Cyclin D1 and beta-catenin proteins ( Figure 4B ). Whether PAK5 gene silencing has a direct effect on the expression of these genes awaits future evaluation.
Discussion
Tumorigenesis is generally driven by the altered expression and/or function of critical genes, particularly those involved in the cell cycle [27, 28] . Deregulation of Rho GTPases and Rho GEFs plays a significant role in oncogenic transformation and metastasis [29] . PAKs that interact with Rho GTPases and Rho GEFs are therefore closely associated with the signaling events that propagate cell transformation and tumor formation [30] . Integrins and the small GTPases Cdc42 and Rac, whose targets are the PAK family, also play an important role in tumorigenesis. Previous studies have demonstrated that group II PAK activity can influence cancer-cell behavior [31] . PAK4 is closely associated with the progression and metastasis of breast cancer [32] , the adhesion of prostate cancer cells [33] and the migration of human gastric cancer cells [34] , and PAK6 is overexpressed in prostate cancer and breast cancer cell lines [29, 35] . Several studies have provided detailed insights into the role of the PAK5 protein in colorectal cancer [15, 16] and pancreatic [17] . However, the role of PAK5 in HCC tumorigenesis remains poorly understood. In the present study, we first compared PAK5 gene expression in HCC versus matched paraneoplastic tissues and tumor cell lines of different origins. The PAK5 mRNA was significantly elevated in 25 of 30 (83.33%, P<0.05) patient samples, suggesting that PAK5 might play a role in tumor formation, maintenance, and/or progression. Of the six tumor cell lines investigated, four expressed significant levels of PAK5 protein, and the highest expression was observed in the HepG2 HCC cells; in contrast, the HL-7702 liver cells and the SK-HEP-1 HCC cells expressed PAK5 at very low levels.
Subsequently, we employed a strategy to silence PAK5 using a lentiviral vector-based RNAi in HepG2 cells to assess the biological consequences of PAK5 knockdown. Consistent with PAK5's role as a cell cycle regulatory molecule, PAK5 gene silencing slowed cell proliferation, most likely by arresting the cells in the G 1 phase (Figure 3 ). Our future research will study the crosstalk between the DNA replication function of PAK5 and the G 1 phase arrest observed in the current work. Furthermore, we found that PAK5 silencing in HepG2 cells reduced colony formation in soft agar, and most importantly, significantly reduced the tumor size in nude mouse xenografts. These results together demonstrated that PAK5 plays an important role in tumorigenesis. The tumor data are quite striking as mice injected with cells expressing the shRNA against PAK5 had no visible tumors in contrast to the control mice ( Figure 3D ). Genetic evidence supports a role for Cyclin D1 and beta-catenin activation in HCC [21] [22] [23] [24] [25] [26] , and our results indicated that silencing of PAK5 gene expression significantly decreased Cyclin D1 and beta-catenin mRNA and protein, although the exact mechanism requires further study. This result is consistent with the reduced tumorigenicity of HepG2 cells upon PAK5 gene silencing.
In summary, our study utilized PAK5 gene silencing to elucidate the role of PAK5 in the proliferation and tumorigenicity of HCC cells. Thus, PAK5 may prove to be an effective therapeutic target or perhaps serve as a clinical diagnostic or prognostic marker in human HCC. 
